Back to Search Start Over

Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis.

Authors :
Falzone, Yuri Matteo
Domi, Teuta
Mandelli, Alessandra
Pozzi, Laura
Schito, Paride
Russo, Tommaso
Barbieri, Alessandra
Fazio, Raffaella
Volontè, Maria Antonietta
Magnani, Giuseppe
Del Carro, Ubaldo
Carrera, Paola
Malaspina, Andrea
Agosta, Federica
Quattrini, Angelo
Furlan, Roberto
Filippi, Massimo
Riva, Nilo
Source :
European Journal of Neurology; Jul2022, Vol. 29 Issue 7, p1930-1939, 10p
Publication Year :
2022

Abstract

Background and purpose: This study was undertaken to determine the diagnostic and prognostic value of a panel of serum biomarkers and to correlate their concentrations with several clinical parameters in a large cohort of patients with amyotrophic lateral sclerosis (ALS). Methods: One hundred forty‐three consecutive patients with ALS and a control cohort consisting of 70 patients with other neurodegenerative disorders (DEG), 70 patients with ALS mimic disorders (ALSmd), and 45 healthy controls (HC) were included. Serum neurofilament light chain (NfL), ubiquitin carboxyl‐terminal hydrolase isozyme L1 (UCHL1), glial fibrillary acidic protein (GFAP), and total tau protein levels were measured using ultrasensitive single molecule array. Results: NfL correlated with disease progression rate (p < 0.001) and with the measures of upper motor neuron burden (p < 0.001). NfL was higher in the ALS patients with classic and pyramidal phenotype. GFAP was raised in ALS with cognitive–behavioral impairment compared with ALS with normal cognition. NfL displayed the best diagnostic performance in discriminating ALS from HC (area under the curve [AUC] = 0.990), DEG (AUC = 0.946), and ALSmd (AUC = 0.850). UCHL1 performed well in distinguishing ALS from HC (AUC = 0.761), whereas it was not helpful in differentiating ALS from DEG and ALSmd. In multivariate analysis, NfL (p < 0.001) and UCHL1 (p = 0.038) were independent prognostic factors. Survival analysis combining NfL and UCHL1 effectively stratified patients with lower NfL levels (p < 0.001). Conclusions: NfL is a useful biomarker for the diagnosis of ALS and the strongest predictor of survival. UCHL1 is an independent prognostic factor helpful in stratifying survival in patients with low NfL levels, likely to have slowly progressive disease. GFAP reflects extramotor involvement, namely cognitive impairment or frontotemporal dementia. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
13515101
Volume :
29
Issue :
7
Database :
Complementary Index
Journal :
European Journal of Neurology
Publication Type :
Academic Journal
Accession number :
157396728
Full Text :
https://doi.org/10.1111/ene.15321